Predictive Value of Positive Drug Screening Results in an Urban Outpatient Population.
暂无分享,去创建一个
[1] J. Genzen,et al. A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory. , 2016, Journal of analytical toxicology.
[2] M. Huestis,et al. One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. , 2015, Journal of Analytical Toxicology.
[3] E. Cone,et al. Metabolism and Disposition of Prescription Opioids: A Review. , 2015, Forensic science review.
[4] Frederick G. Strathmann,et al. A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. , 2015, American journal of clinical pathology.
[5] T. Robert,et al. Immunoassay in healthcare testing applications. , 2015, Journal of opioid management.
[6] G. Reisfield,et al. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results. , 2015, Journal of analytical toxicology.
[7] Z. Chik,et al. Quantitation of methadone and metabolite in patients under maintenance treatment. , 2014, Journal of analytical toxicology.
[8] Robert L Fitzgerald,et al. False-positive interferences of common urine drug screen immunoassays: a review. , 2014, Journal of analytical toxicology.
[9] G. McMillin,et al. Demystifying Analytical Approaches for Urine Drug Testing to Evaluate Medication Adherence in Chronic Pain Management , 2013, Journal of pain & palliative care pharmacotherapy.
[10] M. Tanasijevic,et al. Significant cost savings achieved by in-sourcing urine drug testing for monitoring medication compliance in pain management. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[11] A. Pesce,et al. Observations on the metabolism of morphine to hydromorphone in pain patients. , 2012, Journal of analytical toxicology.
[12] Hans Hansen,et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. , 2012, Pain physician.
[13] L. Manchikanti,et al. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing. , 2011, Pain physician.
[14] L. Manchikanti,et al. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. , 2011, Pain physician.
[15] A. Fallgatter,et al. False-positive methadone drug screens during quetiapine treatment. , 2010, Journal of Clinical Psychiatry.
[16] G. Reisfield,et al. Unexpected urine drug testing results in a hospice patient on high-dose morphine therapy. , 2009, Clinical chemistry.
[17] G. Reisfield,et al. Rational use and interpretation of urine drug testing in chronic opioid therapy. , 2007, Annals of clinical and laboratory science.
[18] A. Hofer,et al. Quetiapine cross reactivity with urine methadone immunoassays. , 2007, The American journal of psychiatry.
[19] W. Clarke. Contemporary Practice in Clinical Chemistry , 2006 .